Table 2 Interactions between bacterial metabolites and drugs relevant in ovarian cancer chemotherapy
Drug | Metabolite | Effect | Ref. |
|---|---|---|---|
Cisplatin | Spermine, spermidine | induce cisplatin resistance | Marverti et al. 2005; Marverti et al. 2004; Marverti et al. 2001; Marverti et al. 1997; Hector et al. 2004; Desiderio et al. 1997 |
Butyrate and valproic acid | Mrkvicova et al. 2019; Wasserman et al. 1989; Sajadpoor et al. 2018 | ||
Paclitaxel | LPS | TLR4 activation induces paclitaxel chemoresistance | Kelly et al. 2006; Edwardson et al. 2017; Huang et al. 2014; Szajnik et al. 2009 |
Doxorubicin/Adriamycin | Taurochenodeoxycholate | sensitizes resistant cells | Schuldes et al. 2001 |
Butyrate and valproic acid | Wasserman et al. 1989 | ||
Spermine | induces Doxorubicin resistance | Schuldes et al. 2001 | |
Niraparib | Butyrate and valproic acid | sensitizes resistant cells | Booth et al. 2018 |
Topoisomerase II inhibitors (TopoIIi) | Spermine, spermidine | sensitizes cells to TopoIIi | Desiderio et al. 1997 |
Mitomycin | Taurochenodeoxycholate | sensitizes | Schuldes et al. 2001 |